Evidence map›Paper›PMID 41290699›Full record

Trial reportNature communications2025

Whole-body CD8

Janneke W de Boer, Kylie Keijzer, Jaap A van Doesum, Nienke A M Smit, Adrienne H Brouwers, Joyce van Sluis, Marjolijn N Lub-de Hooge, Frank R Pierik, Gerwin A Huls, Lisanne V van Dijk and 9 more

Erratum issuedAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Janneke W de Boer *Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-0221-1835
Kylie Keijzer *Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-8348-0438
Jaap A van Doesum *Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Nienke A M SmitDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Adrienne H BrouwersDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0003-2698-1516
Joyce van SluisDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0003-1908-4518
Marjolijn N Lub-de HoogeClinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-5390-2791
Frank R PierikClinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-7304-4173
Gerwin A HulsDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Lisanne V van DijkDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Lydia VisserDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Arjan DiepstraDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0001-9239-1050
Walter NoordzijDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Simon P WilliamsGenentech Inc., San Francisco, CA, USA.
Alexander UngewickellGenentech Inc., San Francisco, CA, USA.
Sjoerd G EliasDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-3903-4024
Elisabeth G E de VriesDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0000-0002-8949-7425
Anne G H NiezinkDepartment of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID http://orcid.org/0009-0009-2860-8767
Tom van MeertenDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. t.van.meerten@umcg.nl.ORCID http://orcid.org/0000-0002-5581-6950

Funding

Genentech (Genentech, Inc.) made available to the instititution
6 · The paper itself

Abstract

Chimeric antigen receptor T-cell therapy (CART) has revolutionized the treatment of patients with refractory/relapsed large B-cell lymphoma (R/R LBCL). Limited biopsy data indicate that a higher activated CD8

Indexed as

Antigens, CD19CD8-Positive T-LymphocytesImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffusePositron-Emission TomographyWhole Body ImagingAdultAgedFemaleHumansMaleMiddle AgedRadioisotopesReceptors, Chimeric AntigenZirconiumAntigens, CD19RadioisotopesReceptors, Chimeric AntigenZirconiumZirconium-89

Identifiers

PMID41290699
PMCPMC12749833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.